Navigation Links
Flaw in Alzheimer's drug trial test
Date:12/16/2012

New research led by Plymouth University Peninsula Schools of Medicine and Dentistry suggests that the cognitive test used in Alzheimer's drug trials is flawed.

The current standard cognitive test for the disease is the ADAS Cog. The new research, published as two studies in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, investigates the role of the test and questions its effectiveness.

The studies show that the ADAS Cog is not subtle enough to properly track changes in the early stages of Alzheimer's. This is important because data from this key stage is required to show whether or not a new drug is working. The study also showed that the modern method of "Rasch analysis" confirmed the flaw.

In their first study, the researchers examined 675 measurements from people, aged 53 to 90, with mild Alzheimer's disease across five time points 0, six, 12, 18 and 24 months. In terms of final patient score the ADAS-cog seemed sound. But by breaking down all the data to component level, a different story emerged. A "ceiling effect" was exposed for eight out of the 11 parts of the ADAS-cog with many patients ranging from 32 to 83 per cent - "passing" the section when in reality much greater variance between the patients almost certainly existed and needed scoring.

In the second study, the research team moved on to use the modern method of "Rasch analysis" to further test the data. This confirmed the flaw. The more sophisticated method of analysis also suggested a number of possible pathways to improvement including making parts of the ADAS-cog test more difficult as well as re-thinking the scoring structure.

As a consequence, the Plymouth-based research team is suggesting urgent changes to the ADAS Cog and is not ruling out the need for a new test.

The study was led by Professor Jeremy Hobart. He said: "It is impossible to say precisely the extent to which the ADAS Cog's flaws have undermined the numerous clinical trials in which it has been used. It has been used, unchanged, for many years and its apparent contribution to suboptimal trials has led a number of drug companies to rethink their strategies. However, it is very clear that in its current form the ADAS Cog underestimates cognitive differences between people and changes over time. To determine if treatments, developed from painstaking years of research, work in expensive studies we need to invest in developing measurement instruments that are fit for purpose. This requires the routine use of different methods. In its current form, the ADAS Cog is not working in people with mild Alzheimer's disease."


'/>"/>

Contact: Andrew Gould
andrew.gould@pcmd.ac.uk
44-188-438-346
University of Plymouth
Source:Eurekalert

Related medicine news :

1. A promising clinical trial to reduce the severity of autistic disorders
2. NIH-funded trial launched to assess experimental TB drug
3. Mesothelioma Victims Center Now Offers Its Services To Any Type Of Industrial Worker Diagnosed with Mesothelioma Including Naming the Best Mesothelioma Law Firms
4. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
5. Delkin Devices Inc. Announces SPAN™ Extended Life Cycle Industrial Storage Product Line
6. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
7. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
8. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
9. University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
10. Kentucky study finds common drug increases deaths in atrial fibrillation patients
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers and ... substantially enhances the WellnessPro platform by expanding the treatment modalities available in ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational ... that will inspire the reader to be aware of God's direction in their lives. ... author, Sanford Smith, retired teacher and active church leader. , Sanford says, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink ... Network for connecting the Life Sciences supply chain ... marketplace, today announced that Tjoapack has selected TraceLink,s ... manufacturing customers comply with the rapidly approaching serialization ... Act (DSCSA) in 2017 and the EU Falsified ...
(Date:12/7/2016)... 7, 2016 According to a new market research ... Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, ... is expected to reach USD 1,519.2 Million by 2021 from USD 856.3 ... Continue Reading ... ...
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
Breaking Medicine Technology: